



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 45018

**Title:** Current and future pharmacological therapies for managing cirrhosis and its complications

**Reviewer's code:** 02860895

**Reviewer's country:** Japan

**Science editor:** Jia-Ping Yan

**Date sent for review:** 2018-12-11

**Date reviewed:** 2018-12-16

**Review time:** 5 Hours, 5 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	(General priority)	Peer-reviewer's expertise on the topic of the manuscript:
<input type="checkbox"/> Grade E: Do not publish	<input type="checkbox"/> Grade D: Rejection	<input checked="" type="checkbox"/> Minor revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Major revision	<input type="checkbox"/> General
		<input type="checkbox"/> Rejection	<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

This is a nice review article that comprehensively covers current knowledge concerning pharmacological therapies for cirrhosis and its complications. I appreciate the authors' efforts to have written this article. I could find no major problem. As a minor point,



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

although anticoagulation therapies are explained in the main text, no such description is present in the abstract. I think that a concise explanation about anticoagulation should be added in the abstract because of its importance.

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- The same title
- Duplicate publication
- Plagiarism
- No

##### ***BPG Search:***

- The same title
- Duplicate publication
- Plagiarism
- No



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 45018

**Title:** Current and future pharmacological therapies for managing cirrhosis and its complications

**Reviewer's code:** 00071662

**Reviewer's country:** Turkey

**Science editor:** Jia-Ping Yan

**Date sent for review:** 2018-12-25

**Date reviewed:** 2018-12-25

**Review time:** 5 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input checked="" type="checkbox"/> Yes
			<input type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

I think this review is very important to approach the treatment in these patients

**INITIAL REVIEW OF THE MANUSCRIPT**



# Baishideng Publishing Group

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

### *Google Search:*

- The same title
- Duplicate publication
- Plagiarism
- No

### *BPG Search:*

- The same title
- Duplicate publication
- Plagiarism
- No



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 45018

**Title:** Current and future pharmacological therapies for managing cirrhosis and its complications

**Reviewer's code:** 00506564

**Reviewer's country:** Spain

**Science editor:** Jia-Ping Yan

**Date sent for review:** 2018-12-25

**Date reviewed:** 2019-01-07

**Review time:** 17 Hours, 12 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	(General priority)	Peer-reviewer's expertise on the topic of the manuscript:
<input type="checkbox"/> Grade E: Do not publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Minor revision	<input type="checkbox"/> Advanced
		<input checked="" type="checkbox"/> Major revision	<input checked="" type="checkbox"/> General
		<input type="checkbox"/> Rejection	<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

The review is very interesting and very well written. I have to congratulate the authors on the detailed approach to this topic. There are, however, several details that I think should be corrected before publishing: First, since the review will be published in 2019,



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://www.wjgnet.com**

literature review should be updated until December 2018, Second, Authors should clearly state the aims and specific objectives of the review and formulate literature search accordingly. They mention that “the present article aims to provide an overview of the complete pharmacotherapy currently available for the long-term management of cirrhotic patients as well as an insight into emerging and future directions”. But they do not make a complete revision. Indeed, authors state that “Whilst previous articles have addressed individual pharmacological agents and their role in treating specific complications of cirrhosis”. They are partly approaching this topic the same way, with specific subheadings for individual pharmacologic agents instead of subheadings for complications of cirrhosis. For instance, authors mention hepatorenal syndrome but they do not talk about terlipressin or octeotride. Neither they mention octeotride as a potential treatment for correcting serum sodium in patients with cirrhosis and hyponatremia. In this regard, no specific subheadings are devoted to portopulmonary hypertension, hepatopulmonary syndrome or hepatorenal syndrome (where terlipressin or octeotride may have a role). Similarly, no specific subheading resumes the approach to hepatic encephalopathy and many treatments, such as acarbose or L-ornithine-L-aspartate are neither mentioned as new treatments nor discussed as potentially useful for hepatic encephalopathy. It is particularly surprising that (instead of acarbose, e.g.) caffeine is mentioned and 5 references are used for illustrating this point. But caffeine is not used for treating cirrhosis or any of its complications (and maybe this article should be cited <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783828/> ) To sum up, authors should clearly state which drugs or which specific complications of cirrhosis they are going to review and formulate and structure this narrative review accordingly. In this present form, several important treatments are not covered and the readers may not know if they are just not covered, if they missed or if they do not have a role in the



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

treatment of cirrhosis or its complications.

#### INITIAL REVIEW OF THE MANUSCRIPT

##### *Google Search:*

- The same title
- Duplicate publication
- Plagiarism
- No

##### *BPG Search:*

- The same title
- Duplicate publication
- Plagiarism
- No